<DOC>
	<DOCNO>NCT00059826</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil cisplatin , work different way stop tumor cell divide stop grow die . Interferon alfa may interfere growth tumor cell . Radiation therapy use high-energy radiation x-rays source kill tumor cell . Combining chemotherapy interferon alfa give radiation therapy surgery may kill remain tumor cell . PURPOSE : Phase II trial study effectiveness adjuvant chemoradiotherapy interferon alfa treat patient resected stage I , stage II , stage III pancreatic cancer .</brief_summary>
	<brief_title>Adjuvant Chemoradiotherapy Interferon Alfa Treating Patients With Resected Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine disease-free overall survival patient resect pancreatic adenocarcinoma treat adjuvant chemoradiotherapy comprise fluorouracil , cisplatin , interferon alfa . - Determine rate severity acute late toxic effect patient treat regimen . - Determine local-regional disease control distant disease control patient treat regimen . OUTLINE : This multicenter study . - Chemoradiotherapy ( CRT ) : Patients receive fluorouracil IV continuously day 1-38 ; cisplatin IV 1 hour day 1 , 8 , 15 , 22 , 29 , 36 ; interferon alfa subcutaneously day 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 , 29 , 31 , 33 , 36 , 38 . Patients also undergo radiotherapy day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-38 . - Post-CRT chemotherapy : Beginning 4-6 week completion CRT , patient receive fluorouracil IV continuously day 1-42 . Treatment repeat every 56 day total two course absence disease progression unacceptable toxicity . Patients follow every 2 month 2 year , every 3 month 1 year , every 4 month 1 year , every 6 month 1 year , annually thereafter .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Patient must &gt; 18 year age . 2 . Patient must document ECOG/Zubrod performance status 0 1 , within 7 day prior registration . 3 . Patient must pathological stage T13 , N01 , M0 adenocarcinoma head pancreas accord American Joint Committee Cancer ( AJCC ) stag system . NOTE : The pathology report must submit ACOSOG Pathology Report Shuttle CRF . 4 . Patient must undergo potentially curative gross total resection pancreaticoduodenectomy ( include R0 [ residual tumor ] R1 [ microscopic residual tumor ] ) within 56 day prior begin treatment . NOTE : The operative report must submit ACOSOG Operative Report Shuttle CRF . 5 . Patient must stable increase weight 14 day prior start treatment , otherwise supplemental nutrition ( e.g . feed jejunostomy , PEG , TPN ) must initiate prior start treatment.6 . Patient must adequate bone marrow , hepatic renal function , within 7 day prior registration : WBC &gt; 3,000 mm^3 ANC &gt; 1,500 mm^3 hemoglobin &gt; 9.5 mg/dl platelet count &gt; 100,000 mm^3 total bilirubin &lt; 3 mg/dl AST ( SGOT ) &lt; 2.0 time institutional upper limit normal ( ULN ) ALT ( SGPT ) &lt; 2.0 time institutional ULN alkaline phosphatase &lt; 2.0 time institutional ULN serum creatinine &lt; 1.5 time institutional ULN 7 . Patient must baseline diagnostic CT scan chest CT scan IV contrast ( MRI ) abdomen/pelvis , within 30 day prior registration , exclude metastatic disease . 8 . If female childbearing potential , patient must negative urine serum pregnancy test , within 7 day prior registration . NOTE : Postmenopausal woman must amenorrheic least 12 consecutive month consider childbearing potential . 9 . Patient ( male female ) reproductive potential must agree use medically acceptable contraception study . NOTE : Medically acceptable contraceptive include : ( 1 ) surgical sterilization , ( 2 ) approve hormonal contraceptive ( birth control pill , DepoProvera , Lupron Depot ) , ( 3 ) barrier method ( condom diaphragm ) use spermicide , ( 4 ) intrauterine device ( IUD ) . 10 . Patient , patient 's legally acceptable representative , must sign date inform consent PRIOR registration performance study related procedure . 11 . Patient , patient 's legally acceptable representative , must provide write authorization allow use disclosure protect health information . NOTE : This may obtain either studyspecific informed consent separate authorization form must obtain patient prior study registration . 12 . If patient cancer survivor , follow criterion must meet documented patient 's medical record : 1 . Patient undergone potentially curative therapy prior malignancy . 2 . No evidence prior malignancy least 5 year ( except successfully treat cervical carcinoma situ , lobular carcinoma situ breast , nonmelanoma skin cancer ) . 3 . No evidence recurrence prior malignancy . 1 . Patient pancreaticoduodenectomy histopathology adenosquamous carcinoma , ampullary carcinoma , carcinoid tumor , cystadenocarcinoma , cystadenoma , distal common bile duct carcinoma , duodenal carcinoma , islet cell carcinoma . 2 . Patient pregnant lactating . 3 . Patient recurrent pancreatic cancer . 4 . Patient receive prior systemic chemotherapy radiotherapy pancreatic cancer . 5 . Patient receive external beam photon ( xray ) therapy chest , abdomen pelvis . 6 . Patient receive biologic/ immunologic therapy . 7 . Patient receive chronic immunotherapy ( e.g . prednisone methotrexate ) collagen vascular disease chronic immunologic abnormality . 8 . Patient preexist psychiatric condition , especially depression , history severe psychiatric disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>